EPLERENONE 25MG FILM-COATED TABLETS
Active substance(s): EPLERENONE / EPLERENONE / EPLERENONE
Inspra® 25mg film-coated Tablets / Eplerenone 25mg film-coated Tablets
Inspra® 50mg film-coated Tablets / Eplerenone 50mg film-coated Tablets
This medicine is available as any of the above names but will be referred to as Inspra throughout the following
Read all of this leaflet carefully before you start taking this medicine because it contains important
information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. See section 4.
What is in this leaflet:
1. What Inspra is and what it is used for
2. What you need to know before you take Inspra
3. How to take Inspra
4. Possible side effects
5. How to store Inspra
6. Contents of the pack and other information
1. WHAT INSPRA IS AND WHAT IT IS USED FOR
Inspra belongs to a group of medicines known as selective aldosterone blocking agents. These blocking agents
inhibit the action of aldosterone, a substance produced within the body, which controls your blood pressure and
heart function. High levels of aldosterone can cause changes in your body that lead to heart failure.
Inspra is used to treat your heart failure to prevent worsening and reduce hospitalisations if you have:
1. had a recent heart attack, in combination with other drugs that are used to treat your heart failure, or
2. have persistent, mild symptoms despite the treatment you have been receiving so far.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE INSPRA
Do not take Inspra
• if you are allergic to eplerenone or any of the other ingredients of this medicine (listed in section 6).
• if you have high levels of potassium in your blood (hyperkalemia)
• if you are taking groups of drugs which help you to excrete excessive body fluid (potassium sparing diuretics)
• if you have severe kidney disease
• if you have severe liver disease
• if you are taking medicines that are used to treat fungal infection (ketoconazole or itraconazole)
• if you are taking antiviral medication for treating HIV (nelfinavir or ritonavir)
• if you are taking antibiotics used to treat bacterial infections (clarithromycin or telithromycin)
• if you are taking nefazodone used to treat depression.
• if you are taking medicines used to treat certain heart conditions or hypertension (so called angiotensin
converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)) together.
Warnings and precautions
Talk to your doctor or pharmacist or nurse before taking Inspra.
• if you have kidney or liver disease (see also “Do not take Inspra”)
• if you are taking lithium (usually given for manic depressive disorder, also called bipolar disorder)
• if you are taking tacrolimus or cyclosporin (used to treat skin conditions such as psoriasis or eczema, and to
prevent rejection after organ transplantation)
Children and adolescents
The safety and efficacy of eplerenone in children and adolescents have not been established.
Other medicines and Inspra
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
• Itraconazole or ketoconazole (used to treat fungal infections), ritonavir, nelfinavir (antiviral medication for
treating HIV), clarithromycin, telithromycin (used to treat bacterial infections) or nefazodone (used to treat
depression) as these drugs reduce the break-down of Inspra, thereby prolonging its effect on the body.
• Potassium sparing diuretics (drugs which help you to excrete excess body fluid) and potassium supplements
(salt tablets) as these drugs increase the risk of high potassium levels in your blood.
• Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) together (which are
used to treat high blood pressure, heart disease or particular kidney conditions) as these drugs may increase
the risk of high potassium levels in your blood.
• Lithium (usually given for manic depressive disorder, also called bipolar disorder). Use of lithium together with
diuretics and ACE inhibitors (used to treat high blood pressure and heart disease) has been shown to cause
levels of lithium in the blood to become too high, which may cause side effects of: loss of appetite; visual
impairment; tiredness; muscle weakness; muscle twitches.
• Cyclosporin or tacrolimus (used to treat skin conditions such as psoriasis or eczema, and to prevent rejection
after organ transplantation). These drugs can cause kidney problems and therefore increase the risk of high
potassium levels in your blood.
• Non-steroidal anti-inflammatory drugs (NSAIDs - certain pain killers such as ibuprofen, used to relieve pain,
stiffness and inflammation). These drugs may lead to kidney problems and therefore increase the risk of high
potassium levels in your blood.
• Trimethoprim (used to treat bacterial infections) may increase the risk of high potassium levels in your blood.
• Alpha I blockers, such as prazosin or alfuzosin (used to treat high blood pressure and particular prostate
conditions) may lead to a fall in blood pressure and dizziness upon standing.
• Tricyclic antidepressants such as amitryptyline or amoxapine (for treatment of depressions), antipsychotics
(also known as neuroleptics) such as chlorpromazine or haloperidol (for the treatment of psychiatric disorders),
amifostine (used during cancer chemotherapy) and baclofen (used to treat muscle spasm). These drugs may
lead to a fall in blood pressure and dizziness upon standing.
• Glucocorticoids, such as hydrocortisone or prednisone (used to treat inflammation and certain skin conditions)
and tetracosactide (mainly used for diagnosing and treating disorders of the adrenal cortex) may reduce the
blood-pressure lowering effect of Inspra.
• Digoxin (used in the treatment of heart conditions). Digoxin blood levels may be increased when taken together
• Warfarin (an anti-clotting drug): Caution is warranted when taking warfarin because high levels of warfarin in the
blood may cause changes in the effect of Inspra on the body.
• Erythromycin (used to treat bacterial infections), saquinavir (antiviral medication for treating HIV), fluconazole
(used to treat fungal infections), amiodarone, diltiazem and verapamil (for the treatment of heart problems and
high blood pressure) reduce the break-down of Inspra thereby prolonging the effect of Inspra on the body.
• St John’s Wort (herbal medicinal product), rifampicin (used to treat bacterial infections), carbamazepine,
phenytoin, and phenobarbital (used, among others, to treat epilepsy) may increase the break-down of Inspra
and thus decrease its effect.
Inspra with food and drink
Inspra may be taken with or without food.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or
pharmacist for advice before taking this medicine. The effect of Inspra has not been evaluated during pregnancy in
It is not known if eplerenone is excreted in human breast milk. A decision should be made with your doctor,
whether to discontinue breast-feeding or to discontinue the drug.
Driving and using machines
You may feel dizzy after taking Inspra. If this should happen, do not drive or operate machinery.
Inspra contains lactose monohydrate
Inspra contains lactose monohydrate (a type of sugar). If you have been told by your doctor that you have an
intolerance to some sugars, contact your doctor before taking this medicinal product.
3. HOW TO TAKE INSPRA
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist
if you are not sure.
Inspra tablets may be taken together with food or on an empty stomach. Swallow the tablets whole with plenty of
Inspra is usually administered together with other medication for heart failure e.g. beta blockers. The usual starting
dose is one 25 mg tablet once daily, increasing after about 4 weeks to 50 mg once daily (either as one 50 mg tablet
or two 25 mg tablets). The maximum dose regimen is 50 mg daily.
Blood potassium levels should be measured before starting Inspra therapy, within the first week and at one month
after the start of treatment or after a change in dose. The dose may be adjusted by your doctor, depending on the
potassium levels in your blood.
If you have mild kidney disease, you should start on one 25 mg tablet every day. And if you have moderate kidney
disease, you should start on one 25 mg tablet every other day. These doses may be adjusted if your doctor
recommends and according to your blood potassium levels.
In patients with severe kidney disease, Inspra is not recommended.
In patients with mild-to-moderate liver disease no adjustment of the starting dose is required. If you have liver or
kidney problems, you may need more frequent testing of your blood potassium levels (see also “Do not take
For the elderly: no adjustment of the starting dose is required.
For children and adolescents: Inspra is not recommended.
If you take more Inspra than you should
If you take more Inspra than you should, tell your doctor or pharmacist immediately. If you have taken too much of
your medicine, the most likely symptoms will be low blood pressure (expressed as a light feeling in your head,
dizziness, blurred vision, weakness, acute loss of consciousness) or hyperkalemia, high levels of potassium in the
blood (expressed by muscle cramps, diarrhoea, nausea, dizziness or headache).
If you forget to take Inspra
If it is almost time for your next tablet, skip the tablet you missed and take your next tablet when it is due.
Otherwise take the tablet as soon as you remember, providing there is more than 12 hours to when you are due to
take your next tablet. Then go back to taking your medicine as you would normally.
Do not take a double dose to make up for the forgotten tablet.
If you stop taking Inspra
It is important to keep taking Inspra as prescribed unless your doctor tells you to stop your treatment.
If you have any further questions on the use of this medicine ask your doctor or pharmacist.
4. POSSIBLE SIDE EFFECTS
Like all medicines this medicine can cause side effects, although not everybody gets them.
If you experience any of the following:
You should seek immediate medical attention
• swollen face, tongue or throat
• difficulty swallowing
• hives and difficulties breathing
These are the symptoms of angioneurotic oedema, an uncommon (affecting up to 1 in 100 people) side effect.
Other reported side effects include:
Common side-effects (may affect up to 1 in 10 people):
• elevated potassium level in your blood (symptoms include muscle cramps, diarrhoea, nausea, dizziness or
• elevated quantity of cholesterol in your blood
• insomnia (difficulty sleeping)
• heart complaints e.g., irregular heartbeat and heart failure
• low blood pressure
• abnormal functioning of your kidney
• back pain
• feeling weak
• muscle spasm
• increased urea level in the blood
• increased creatinine blood levels which may indicate kidney problems
Uncommon side-effects (may affect up to 1 in 100 people):
• eosinophilia (increase in certain white blood cells)
• low sodium blood levels
• elevated quantity of triglycerides (fats) in your blood
• fast heart beat
• inflammation of the gall bladder
• decreased blood pressure that can cause dizziness upon standing
• thrombosis (blood clot) in the leg
• sore throat
• underactive thyroid
• increase in blood glucose
• reduced sense of touch
• increased sweating
• musculoskeletal pain
• feeling generally unwell
• kidney inflammation
• enlargement of breasts in men
• changes in some blood test results
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this
5. HOW TO STORE INSPRA
• Keep out of the sight and reach of children.
• This medicinal product does not require any special storage instructions.
• Do not use this medicine after the expiry date which is stated on the pack and blister after EXP. The expiry date
refers to the last day of that month.
• If your tablets show visible signs of deterioration, show it to a pharmacist who will advise you what to do.
• Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away
medicines you no longer use. These measures will help protect the environment.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Inspra contains
• Each film-coated tablet contains 25mg or 50mg eplerenone.
• The other ingredients are: lactose monohydrate, microcrystalline cellulose (E460), croscarmellose sodium
(E468), hypromellose (E464), sodium lauryl sulfate, talc (E553b) and magnesium stearate (E470b).
• The opadry yellow coating of Inspra 25mg and 50mg film-coated tablets contain hypromellose (E464), titanium
dioxide (E171), macrogol 400, polysorbate 80 (E433), yellow iron oxide (E172) and red iron oxide (E172).
What Inspra looks like and contents of the pack
The Inspra 25mg film-coated tablet is a yellow coloured diamond shaped film-coated tablet marked "NSR" over
"25" on one side and plain on the other side.
The Inspra 50mg film-coated tablet is a yellow coloured diamond shaped film-coated tablet marked "NSR" over
"50" on one side and plain on the other side.
Inspra is available in blister packs of 30 tablets.
PL No: 15814/1061 Inspra® 25mg film-coated Tablets / Eplerenone 25mg film-coated Tablets
PL No: 15814/1062 Inspra® 50mg film-coated Tablets / Eplerenone 50mg film-coated Tablets
Inspra is manufactured by Pfizer PGM, Zone Industrielle - 29 route des Industries, 37530 Poce-sur-Cisse, France.
Procured from within the EU and repackaged by the Product Licence holder: O.P.D. Laboratories Ltd., Unit 6
Colonial Way, Watford, Herts WD24 4PR.
Leaflet revision and issue date (Ref.): 19.06.2017.
Inspra is a registered trade mark of Pfizer Group of companies.
To request a copy of this in Braille, large print or audio
please call 01923 332 796.
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.